MALVERN, Penn., December 02, 2022 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (the “Company” or “Baudax Bio”) BXRX, a pharmaceutical company focused on acute care therapeutics, today announced pricing for a public offering of a total of 1,042,787 common shares (or prefunded warrants instead) of Series A-3 Warrants to purchase up to 1,042,787 common shares and Series A-4 warrants to purchase 1,042,787 common shares at a public offering price of $4.795 per share (or prefunded warrant) and accompanying warrants. The Series A-3 Warrants have an exercise price of $4.50 per share, are exercisable immediately upon issuance and expire five years from the date of issuance, and the Series A-4 Warrants have an exercise price of $4.50 per share. is exercisable immediately upon issuance and expires thirteen months from the date of issuance. Closing of the offering is expected to occur on or about December 6, 2022, subject to satisfaction of customary closing conditions.

HC Wainwright & Co. is acting as the exclusive placement agent for the offering.

Gross proceeds from the offering, before deducting placement agent fees and other offering costs, are expected to be approximately $5 million. The Company intends to use the net proceeds from this offering for working capital, pipeline development activities and general corporate purposes.

The securities described above are being offered pursuant to a registration statement on Form S-1 (File Number 333-268251) filed by the Securities and Exchange Commission (the “SEC”) on December 2, 2022. The offering is being made solely by means of a prospectus, which forms part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus, where available, are available at the SEC’s website at http://www.sec.gov…